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Summary
Background: The purpose of this study was to determine the clinical and laboratory character-
istics in patients with acute myocardial infarction (AMI) associated with coronary vasospasm.
Methods and results: Consecutive 231 patients with documented coronary vasospasm by
ergonovine provocation test but with a normal-appearing coronary angiogram were divided
into two groups, variant angina pectoris (VAP) patients (group I; n = 202, 49.5± 11.1 years)
and AMI patients (group II; n = 29, 47.4± 11.2 years). Matched control patients were 84 AMI
patients with signiﬁcant stenosis (>50%) (group III; n = 84, 61.2± 11.8 years). Although, the
incidence of hypertension, diabetes mellitus, and smoking were lower in group I than in
group III, there was no difference between group II and III (diabetes, 7.9% vs. 13.8% vs.
29.8%; hypertension, 19.8% vs. 24.1% vs. 41.7%; smoking 48% vs. 48.3% vs. 61.9%; respec-
tively, p < 0.01). Measured high-sensitivity C-reactive protein (hsCRP) and ﬁbrinogen level
were higher (respectively, p < 0.001, p < 0.001) in groups II and III (group II, 1.88± 2.9mg/dl,
317.5± 51.2mg/dl; group III, 2.92± 3.9mg/dl, 326.8± 107.7mg/dl) than those in group I
(0.68± 1.5mg/dl, 263.2± 70.3mg/dl). A correlation was clearly seen between ﬁbrinogen and
hsCRP (r = 0.472, p < 0.001).
Conclusion: The clinical characteristics of patients with AMI associated with spasm were similar
to those with VAP, but laboratory ﬁndings were similar to those of AMI in patients with signiﬁcant
stenosis.
© 2010 Japanese College of Car
∗ Corresponding author. Tel.: +82 62 220 6243; fax: +82 62 228 7174.
E-mail address: myungho@chollian.net (M.H. Jeong).
914-5087/$ — see front matter © 2010 Japanese College of Cardiology.
oi:10.1016/j.jjcc.2010.07.008diology. Published by Elsevier Ireland Ltd. All rights reserved.
Published by Elsevier Ireland Ltd. All rights reserved.
m
W
b
r
E
t
a
i
i
t
t
i
v
a
d
s
w
B
b
a
i
W
r
w
i
I
S
B
L
w
W
w
u
w
s
m
a
w
p
R
T
t
p
w
y
r
f
(
(
h
2Characteristics of AMI with coronary vasospasm
Introduction
Variant angina pectoris (VAP) is a disease by which a tran-
sient abrupt marked reduction in the luminal diameter of
an epicardial coronary artery leads to myocardial ischemia.
This is characterized by spontaneous episodes of angina
associated with ST segment elevation on electrocardiogram
(ECG) and documented spasm of epicardial coronary artery
by coronary angiography (CAG). It was initially described
by Prinzmetal in 1959 [1—3]. Generally, patients with VAP
responding to vasodilators such as nitrate have a good
prognosis, but 7.4% of them progress to acute myocardial
infarction with vasospasm (VAMI) [4].
The pathogenesis, predisposing factors, and risk factors
for VAMI are not well known. Currently, several contribut-
ing factors have been identiﬁed. They include thrombin
activation and ﬁbrin formation induced by coronary spasm.
Impaired ﬁbrinolytic activity, reported in patients with
variant angina, suggests that coronary spasm may trig-
ger thrombus formation in coronary arteries and that the
reduction in ﬁbrinolytic activity may slow the removal of
thrombus, ultimately leading to acute myocardial infarction
(AMI) in some patients [5,6]. Fibrinogen, the precursor of
ﬁbrin can promote the development of atherosclerosis and
thrombosis. Fibrinogen can be a precursor of mural thrombi,
which is important in the pathogenesis of acute coronary
syndrome [7—13]. Lipoprotein(a) [Lp(a)] plays an important
part in the genesis of thrombotic coronary occlusion sub-
sequent to spasm because of a particular feature of its
structure that is homology between apolipoprotein (Apo) (a)
and plasminogen [13—15]. Apo B/A1 ratio is a good predictor
of atherosclerotic cardiovascular disease, more so than low-
density lipoprotein (LDL) or high-density lipoprotein (HDL)
cholesterol [16,17]. The cause of development and risk fac-
tors for VAMI are unknown unlike those for AMI with coronary
stenosis (SAMI).
The purpose of this study was to compare the clinical
characteristics of SAMI, VAP, and VAMI, and to analyze the
laboratory ﬁndings such as ﬁbrinogen, Lp(a), Apo B/A1 ratio,
and high-sensitivity C-reactive protein (hsCRP).
Materials and methods
All the subjects were selected from patients who were
hospitalized for CAG because of suspected VAP or of doc-
umented MI during 4 years. We classiﬁed these subjects
into three groups. Consecutive 231 patients with docu-
mented coronary vasospasm with normal-appearing CAG by
ergonovine provocation test were divided into two groups,
VAP (group I; n = 202, 49.5± 11.1 years) and VAMI (group II;
n = 29, 47.4± 11.2 years). And, matched control AMI patients
with signiﬁcant stenosis (diameter stenosis > 50%) [group III
(SAMI); n = 84, 61.2± 11.8 years] were selected randomly
from patients during the same period. Clearly, the deﬁni-
tion of VAP and VAMI were positive result in ergonovine test
with normal-appearing coronary angiogram.AMI was deﬁned by typical chest pain over 20min on
admission, signiﬁcant ST segment elevation on ECG, or
elevation of cardiac enzymes. No patients with hemato-
logic disease, hyperpyrexia (over 38 ◦C), viral, bacterial,
or parasitic infection, sepsis, liver disease, renal failure,
S
v
t
a
p321
alignancy, prosthetic valves, or pacemaker were enrolled.
ritten informed consent was obtained from all the patients
efore entering the study.
CAG was performed by insertion of 5 Fr. or 6 Fr. arte-
ial sheath through the right or left femoral or radial artery.
rgonovine provocation test was carried out after discon-
inuing nitrate, calcium channel blocker, and nicorandil for
t least 3 days. Ergonovine, 5g, 10g, and 30g, was
njected into the left and right coronary arteries separately
n cases without spontaneous spasm at 3-min intervals until
here was a positive result. CAG during ergonovine provoca-
ion test was performed immediately after each ergonovine
njection and 3min later after the injection. A coronary
asospasm was deﬁned as a focal narrowing above 70% or
diffuse narrowing above 90%, reversible with isosorbide
initrate, associated with chest pain and ST segment change
uch as elevation or depression on the ECG. On chest pain,
e tried sublingual nitrate tablet or spray.
Venous blood samples for ﬁbrinogen, hsCRP, Lp(a), Apo
/A1, and lipid proﬁles were withdrawn from the antecu-
ital vein in the supine position without antianginal drugs
t admission. Venous samples were obtained in the fast-
ng state when the subjects were free of any acute illness.
e used the samples that were obtained at discharge. Fib-
inogen (reference value, 180—350mg/dL) was determined
ith System CA-6000 Sysmex system (TOA Medical Electron-
cs Co., Kobe, Japan) using thrombin reagent (Dade Behring
nc., Newark, DE, USA). hsCRP was determined with N High
ensitivity hsCRP (Dade Behring Inc.), Lp(a) was done with
ehring Nephelometer II (Dade Behring Inc.) using N Latex
p(a) reagent (Dade Behring Inc.). Reference value of hsCRP
as below 0.5mg/dL and that of Lp(a) was below 30mg/dL.
Data are expressed as mean± SD. The SPSS program for
indows package (version 11.0; SPSS Inc., Chicago, IL, USA)
as used. Comparisons among the three groups were made
sing one-way analysis of variance (ANOVA). Turkey HSD
as used for odds ratio and multinominal logistic regres-
ion analysis for relative risks. Statistical analysis such as
ultivariate logistic regression was used to evaluate the
ssociation between variables and we display as odds ratio
ith 95% conﬁdence interval (CI). A probability level of
< 0.05 was considered to be statistically signiﬁcant.
esults
he subjects’ clinical characteristics including their risk fac-
ors for coronary artery disease are shown in Table 1. The
atients with VAP and VAMI were younger than the patients
ith SAMI (mean age: 49.5± 11.5 years in VAP; 47.4± 11.2
ears in VAMI; 61.2± 11.8 years in SAMI; p < 0.001). With
egard to the proportion of males to females, the rate of
emales is signiﬁcantly higher in VAP or VAMI than SAMI
male: 133 subjects in VAP (65.8%); 20 (69%) in VAMI; 69
82.1%) in SAMI; p = 0.007). The incidence of diabetes was
igher in SAMI than VAP or VAMI (8.7% in VAP and VAMI vs.
9.8% in SAMI, p < 0.001). Also, a higher rate of smoking in
AMI than VAP or VAMI was observed (48.1% in VAP and VAMI
s. 61.9% in SAMI, p = 0.031), and it was the same with hyper-
ension (20.3% in VAP and VAMI vs. 41.7% in SAMI, p < 0.001)
nd hyperlipidemia (14.7% in VAP and VAMI vs. 40.5% in SAMI,
< 0.001). But, there was no statistically signiﬁcant differ-
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Table 1 Clinical characteristics of the patients.
VAP (n = 202) VAMI (n = 29) SAMI (n = 84)
Age (years) 49.5± 11.5 47.4± 11.2 61.2± 11.8‡
Sex (%)
Male 133(65.8) 20(69.0) 69(82.1)†
Female 69(34.2) 9(31.0) 15(17.9)†
Risk factors (%)
Diabetes 16(7.9) 4(13.8) 25(29.8)†
Smoking 97(48.0) 14(48.3) 52(61.9)†
Hypertension 40(19.8) 7(24.1) 35(41.7)†
Hyperlipidemia 30(14.9) 4(13.8) 18(22.8)
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the current study may have obtained the same results. We
showed that ﬁbrinogen, an index for formation of atheroma-
tous plaque and key to blood ﬂow and platelet aggregation,
was higher in VAMI or SAMI than in VAP. This result indicates
Figure 1 Serum ﬁbrinogen concentrations of the study
groups. Fibrinogen was higher in patients with acute myocar-VAP, vasospastic angina; VAMI, acute myocardial infarction with va
† p < 0.05 vs. VAP.
‡ p < 0.05 vs.VAP and VAMI.
nce between VAP and VAMI in risk factors for coronary
rtery disease (Table 1). The value of LV ejection fraction
EF) was lower in SAMI than that in VAMI (57.8± 8% in VAMI,
2.7± 8% in SAMI, p < 0.01).
The mean value of Lp(a) was higher in SAMI than that in
AP and in VAMI as shown in our results (20.6± 16.1mg/dL in
AP, 29.6± 24.8mg/dL in VAMI, 33.0± 29.2mg/dL in SAMI)
Table 2). The Lp(a) value tended to be higher in VAMI than
hat in VAP, but there was no statistically signiﬁcant dif-
erence. In comparison with the number of patients whose
p(a) was above 25mg/dL, there was a signiﬁcant differ-
nce between VAP and SAMI group (26.3% in VAP vs. 48.2%
n SAMI, p = 0.001), but no signiﬁcant difference between
AP and VAMI despite the larger trend in number in VAMI
han VAP (Table 2). There was a signiﬁcant difference for
DL-cholesterol and HDL-cholesterol between VAP and SAMI,
ut no signiﬁcant difference between VAP and VAMI. Apo
/A1 ratio showed higher value in SAMI than VAP or VAMI
p < 0.001), but no signiﬁcant difference between VAP and
AMI (Table 2).
Fibrinogen was higher in VAMI (317.5± 51.2mg/dL)
nd SAMI (326.8± 107.7mg/dL) than in VAP
263.2± 70.3mg/dL) (p < 0.001, p < 0.001, respectively),
ut showed no signiﬁcant difference between VAMI and
AMI (Fig. 1). hsCRP was higher in VAMI or in SAMI than VAP
0.6± 1.5mg/dL in VAP, 1.8± 2.9mg/dL in VAMI (p = 0.045
s. VAP), 2.9± 3.9mg/dL in SAMI (p < 0.05 vs. VAP)] (Fig. 2,
able 2). Also, signiﬁcant positive correlation between
brinogen and hsCRP was shown (r = 0.472, p < 0.001,
ig. 3).
iscussion
t is well known that vasospasm plays a major role not only
n angina pectoris but also in other acute coronary syn-
romes. Angina pectoris or AMI due to vasospasm is more
revalent in the East, such as in Korea or in Japan than in
he Western countries. Smoking is considered as one of the
ajor risk factors for vasospasm. According to some reports,
agnesium deﬁciency [18], hyperinsulinemia [19], vitamin
deﬁciency [20], high level of Lp(a) [21,22], and hypere-
sinophilia [23] were responsible for vasospasm. Therefore,
isk factors for vasospasm are somewhat different from that
or typical coronary artery disease. Despite smoking being a
d
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Iasm; SAMI: acute myocardial infarction with signiﬁcant stenosis.
ajor predictive factor for vasospasm, smoking incidence in
AP or VAMI was lower than in SAMI in the present study. It
ay be due to a higher proportion of females, whose smok-
ng rate was usually lower than that of men in Korea, in
AP or VAMI than that in SAMI. Also, age and sex differences
etween groups may be responsible for higher incidence of
iabetes and hypertension in SAMI.
Our study showed that Lp(a) in SAMI was signiﬁcantly
igher than that in VAP, but there was no signiﬁcant differ-
nce between Lp(a) in VAMI and that in VAP. These results
re in discord with the reports from Tsuchida et al. [21] and
iwa et al. [24]. But, the current study showed that Lp(a) in
AMI tends to be higher than that in VAP. So, if more subjects
re enrolled or if VAMI due to vasospasm coexistent with
tenosis is included like in the study from Tsuchida et al.,ial infarction with vasospasm (VAMI; Group II) than in those
ith variant angina pectoris (VAP; Group I) and showed no sig-
iﬁcant difference between patients with VAMI and AMI with
oronary stenosis (SAMI; Group III). *p < 0.05, Group I vs. Group
I, Group I vs. Group III.
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Table 2 Fibrinogen, high-sensitivity C-reactive protein, lipoprotein(a), and lipid levels.
VAP VAMI SAMI
Fibrinogen (mg/dL) 263.2 ± 70.3 317.5 ± 51.2† 326.8 ± 107.7†
hsCRP (mg/dL) 0.6 ± 1.5 1.8 ± 2.9† 2.9 ± 3.9†
T-cholesterol (mg/dL) 184 ± 37.8 174.1 ± 45.7 191.5 ± 42.9
LDL (mg/dL) 124.6 ± 33.8 106.8 ± 44.4 135.3 ± 40.7‡
HDL (mg/dL) 50.4 ± 14.7 49.8 ± 11.4 40.3 ± 12.7‡
Triglyceride (mg/dL) 100.6 ± 59.9 108.9 ± 50.2 120.6 ± 63.0
Lp(a)(mg/dL) 20.6 ± 16.1 29.6 ± 24.8 33.0 ± 29.2†
Lp(a) > 25mg/dL 49(26.3%) 9(32.1%) 40(48.2%)†
Apo B/A1 0.8 ± 0.2 0.6 ± 0.2 0.9 ± 0.4‡
hsCRP, high-sensitivity C-reactive protein; T-cholesterol, total cholesterol; LDL, low density lipoprotein; HDL, high density lipoprotein;
VAP, vasospastic angina; VAMI, acute myocardial infarction with vasospasm; SAMI, acute myocardial infarction with stenosis; Lp(a),
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slipoprotein(a); Apo, apolipoprotein.
† p < 0.05 vs. VAP.
‡ p < 0.05 vs. VAP and VAMI.
that increased thrombus may be important in the occurrence
of not only SAMI but also VAMI. However, the precise mecha-
nisms by which coronary spasm leads to coronary thrombosis
and angina or AMI remain unknown. And, in our results, the
myocardial infarction size tended to be smaller in the VAMI
than SAMI group. The impact of infarction between VAMI and
SAMI group may differ. It may inﬂuence the laboratory data.
Possible causes of VAP are endothelial dysfunction, spasm
of vascular smooth muscle, or autonomic nervous dysfunc-
tion [25—27]. And, a possible mechanism of VAMI is that
coronary spasm itself induces formation of thrombus and
impairment of ﬁbrinolysis and consequently MI occurred.
Ogawa et al. [28] reported that the plasma levels of ﬁb-
rinopeptide A, a sensitive marker of thrombin generation,
and plasminogen activator inhibitor (PAI) activity, an indica-
tor of the impairment of ﬁbrinolysis, increased in patients
Figure 2 Serum high-sensitivity C-reactive protein (hs-CRP)
concentrations of the study groups. The hsCRP was higher
in patients with acute myocardial infarction with vasospasm
(VAMI; Group II) or in those with AMI with coronary stenosis
(SAMI; Group III) than in those with variant angina pectoris
(VAP; Group I) (0.6± 1.5mg/dL in VAP, 1.8± 2.9mg/dL in VAMI,
2.9± 3.9mg/dL in SAMI). *p < 0.05, Group I vs. Group II, Group
I vs. Group III.
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lith coronary spastic angina. In general, the turnover of
hrombus depends not only on formation, but also on
ysis. The key components of the ﬁbrinolytic system are
issue-type plasminogen activator (t-PA) and PAI. Fibrinolytic
ctivity reﬂects the balance between t-PA and PAI, and PAI
s a major factor in determining overall ﬁbrinolytic activ-
ty. Zouaoui Boudjeltia et al. [29] reported the relationships
etween euglobulin clot lysis time (ECLT), a test repre-
enting the balance between t-PA and PAI-1 activities, and
ardiovascular risk factors. They advocated that ECLT had a
igniﬁcant relationship with ﬁbrinogen, monocyte, and LDL-
holesterol by multivariate analysis. Funayama et al. [30]
bserved that monocytes modulate the production of t-PA
f endothelial cells in vitro, and that C-reactive protein and
brinogen circulating in the blood can modulate or poten-
iate the production of interleukin-1b and tumor necrosis
actor- by monocytes. The current study showed signiﬁcant
levation of CRP and ﬁbrinogen levels in VAMI than in VAP,
espite not doing analysis for monocytes. This result may
upport the previous theory that impairment of ﬁbrinoly-
igure 3 Relationship between the levels of ﬁbrinogen and
igh-sensitivity C-reactive protein (hs-CRP) showed good corre-
ation (r = 0.472, p < 0.001).
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is has a major role for the development of MI in coronary
pasm. But, although mentioned elevated ﬁbrinogen was
ound to be associated with AMI with coronary spasm, we
o not explain the association between coronary spasm, ﬁb-
inogen, and myocardial infarction in more detail. Because,
AMI patients have the elevation of ﬁbrinogen level, there-
ore elevated ﬁbrinogen level is not thought to be a speciﬁc
henomenon in VAMI.
Sniderman and Rosenbloom [16] emphasized the role of
po B in the development of coronary artery disease. They
uggested that the level of Apo B, and the increased number
nd density of LDL-cholesterol, might be an important coro-
ary risk factor in patients with high level of triglyceride.
n the AMORIS study, they observed that Apo B and Apo A1
ad little inﬂuence by age and sex, compared with the fact
hat LDL-cholesterol had signiﬁcant meaning in men below
0 years [17]. The authors tried to analyze Apo B/A1 ration
etween different groups. The Apo B/A1 ratio in VAMI was
ot signiﬁcantly different compared with that in VAP, but
igniﬁcantly low compared with that in SAMI. These results
xplain that risk factors of coronary vasospasm might be
ifferent compared with typical coronary risk factors. Our
tudy is a single center study with a small sample size.
onclusions
he clinical characteristics of VAMI patients were similar to
atients with VAP, but the laboratory characteristics were
imilar to those patients with SAMI.
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